Medidata Expands Partnership with BeiGene for ePRO Solution
NEW YORK - July 24, 2017 - Medidata, a global provider of cloud-based technology and data analytics for clinical research, announced that BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, will expand its use of the Medidata Clinical Cloud® to further digitize patient reporting for its oncology research studies.
BeiGene will leverage Medidata’s integrated platform to feed eSource Patient Reported Outcome data from Medidata’s Patient Cloud ePRO directly into Medidata Rave®. This infusion of patient recorded outcome data will enable improved operational efficiency, reduced transcription errors and reconciliation issues, and decreased data quality risk plans.
“Our expanded partnership with Medidata will establish a technology platform for our clinical research, which we expect will enable us to more efficiently execute clinical trials of our portfolio compounds,” said Ross Pettit, Senior Vice President of Global Development Operations at BeiGene. “Over the past two years, Medidata has proven to be a key technology partner for BeiGene, with its industry-leading solutions and hands-on approach to our integration needs. By automating paper-based procedures and centralizing patient data on the Medidata platform, we’re able to collaborate globally on our oncology research.”
As part of its expanded partnership with Medidata, BeiGene also plans to standardize the collection and management of safety cases through Medidata Safety Gateway®, a secure, configurable electronic transmission interface between EDC and safety systems. The partnership between BeiGene and Medidata also includes Medidata Coder®, a cloud application that is designed to streamline and centralize medical coding to perform oncology research studies.
“Medidata is proud to be accelerating technology advancement at every level and interaction within the life sciences industry,” said Kara Dennis, Managing Director of Mobile Health at Medidata. “We’ve created an environment that is agile, globally collaborative, and in line with the digital and mobile needs of biotechnology and pharmaceutical companies, all from one unified cloud platform. BeiGene’s forward-thinking technology approach will enable faster study builds and centralized control over patient data, facilitating the evaluation of its portfolio compounds.”
Medidata Contacts
Investor: Anthony D’Amico, Medidata Solutions, +1 732-767-4331, adamico@mdsol.com
Media: Erik Snider, Medidata Solutions, +1 646-362-2997, esnider@mdsol.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
